Glucocorticoids and the risk of osteoporosis

被引:4
作者
Caplan, Liron [1 ]
Saag, Kenneth G. [2 ]
机构
[1] Univ Colorado, Denver Vet Affairs Med Ctr, Denver, CO 80045 USA
[2] Univ Alabama Birmingham, Birmingham, AL USA
关键词
adverse effects; glucocorticoids; osteoporosis; BONE-MINERAL DENSITY; CORTICOSTEROID-INDUCED OSTEOPOROSIS; VERTEBRAL FRACTURE RISK; RECEPTOR GENE POLYMORPHISMS; HIGH-DOSE GLUCOCORTICOIDS; RHEUMATOID-ARTHRITIS; ORAL CORTICOSTEROIDS; POSTMENOPAUSAL WOMEN; PRACTICE PATTERNS; COLLAGEN-SYNTHESIS;
D O I
10.1517/14740330802648194
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Background: Glucocorticoid-induced osteoporosis (GIO) refers to a clinical condition in which a class of corticosteroids increases the susceptibility of bones to fracture. Numerous recent studies have improved our understanding of the underlying biology of this condition, whereas data from randomized controlled trials have provided clinicians with more options for prevention of GIO. Objective: To review the pathophysiology and epidemiology of GIO, as well as current pharmacologic treatment and prevention modalities available. To review the state of healthcare provider concordance with GIO prevention guidelines. Methods: Representative examples of various cellular and molecular processes underlying GIO were included, with an emphasis towards more recent discoveries. The data used to describe the epidemiology of GIO were derived from both randomized controlled studies and observational studies, framed through a discussion of known osteoporosis risk factors. Results/conclusion: Progress has been made in clarifying the pathophysiologic mechanisms that result in GIO. Although the options for preventions and treatment of GIO continue to expand, provider compliance with preventive measures remains suboptimal.
引用
收藏
页码:33 / 47
页数:15
相关论文
共 151 条
[1]
Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: Updated recommendations from the group for the respect of ethics and excellence in science [J].
Abadie, EC ;
Devogealer, JP ;
Ringe, JD ;
Ethgen, DJ ;
Bouvenot, GM ;
Kreutz, G ;
Laslop, A ;
Orloff, JJ ;
Vanderauwera, PM ;
Delmas, PD ;
Dere, WH ;
Branco, J ;
Altman, RD ;
Avouac, BP ;
Menkes, CJ ;
Vanhaelst, L ;
Mitlak, BH ;
Tsouderos, Y ;
Reginster, JYL .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2005, 35 (01) :1-4
[2]
Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis [J].
Adachi, JD ;
Bensen, WG ;
Brown, J ;
Hanley, D ;
Hodsman, A ;
Josse, R ;
Kendler, DL ;
Lentle, B ;
Olszynski, W ;
SteMarie, LG ;
Tenenhouse, A ;
Chines, AA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (06) :382-387
[3]
Adachi JD, 2001, ARTHRITIS RHEUM-US, V44, P202, DOI 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO
[4]
2-W
[5]
Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the department of veterans affairs [J].
Adler, RA ;
Hochberg, MC .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (21) :2619-2624
[6]
Dexamethasone suppresses in vivo levels of bone collagen synthesis in neonatal mice [J].
Advani, S ;
LaFrancis, D ;
Bogdanovic, E ;
Taxel, P ;
Raisz, LG ;
Kream, BE .
BONE, 1997, 20 (01) :41-46
[7]
THE EFFECT OF GLUCOCORTICOIDS ON BONE MASS IN RHEUMATOID-ARTHRITIS PATIENTS - INFLUENCE OF MENOPAUSAL STATE [J].
ALS, OS ;
GOTFREDSEN, A ;
CHRISTIANSEN, C .
ARTHRITIS AND RHEUMATISM, 1985, 28 (04) :369-375
[8]
The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: A meta-regression [J].
Amin, S ;
Lavalley, MP ;
Simms, RW ;
Felson, DT .
JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 (08) :1512-1526
[9]
High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: A cross-sectional outpatient study [J].
Angeli, Alberto ;
Guglielmi, Giuseppe ;
Dovio, Andrea ;
Capelli, Giovanni ;
de Feo, Daniela ;
Giannini, Sandro ;
Giorgino, Ruben ;
Moro, Luigi ;
Giustina, Andrea .
BONE, 2006, 39 (02) :253-259
[10]
[Anonymous], HLTH TECHNOL ASSESS